Emotion recollected in tranquility: lessons learned from the COX-2 saga

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Drug Safety

Background:

• Nonsteroidal anti-inflammatory drugs (NSAIDs) target cyclooxygenase (COX) enzymes 1 and 2.
• COX-2 selective NSAIDs offer gastrointestinal benefits over traditional NSAIDs.
• However, COX-2 inhibitors are linked to increased cardiovascular adverse events.

Purpose of the Study:

• To investigate the mechanisms behind cardiovascular risks associated with COX-2 selective NSAIDs.
• To understand the role of COX-2-dependent prostaglandins in cardiovascular protection.
• To draw lessons for drug surveillance, regulation, and personalized medicine.

Main Methods:

• Review of human pharmacology and genetics data.
• Analysis of studies involving genetically manipulated rodents.
• Examination of findings from other animal models and randomized trials.

Main Results:

• Evidence indicates that COX-2 selective NSAIDs suppress cardioprotective prostaglandins, notably prostacyclin.
• This suppression is linked to adverse cardiovascular events, including heart failure, myocardial infarction, and stroke.
• The cardiovascular risks are a consequence of inhibiting COX-2-dependent pathways.

Conclusions:

• The cardiovascular risks of COX-2 selective NSAIDs stem from the inhibition of essential cardioprotective prostacyclin.
• Lessons from this drug class inform approaches to drug surveillance, regulatory oversight, and personalized risk-benefit assessments.
• A more personalized approach to drug efficacy and risk management is warranted.